Vascular Biogenics Ltd. (NASDAQ:VBLT) headquartered in Modiin, will host a conference call for the investment community to discuss the 3Q20 earnings result on 16th November 2020 at 8:30 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.vblrx.com
Individuals interested in participating in the audio call may dial the listen only number(s) 877-407-9208 Toll Free or 201-493-6784 Toll Number, with passcode : 13711944
Earnings Expectation
Vascular Biogenics Ltd. clinical-stage biopharmaceutical firm, is expected to report third quarter earnings results, before market open, on Monday 16th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.13 per share from revenue of $ 0.17 million. Looking ahead, the full year loss are expected at $ 0.55 per share on the revenues of $ 0.80 million.
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The companys program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer.
